Effect of a hydrophilic and a hydrophobic statin on cardiac salvage after ST-elevated acute myocardial infarction - A pilot study

Atherosclerosis

Volumn 237, Issue 1, 2014, Pages 251-258

  Chitose, Tadasuke ^a,c   Sugiyama, Seigo ^a,e   Sakamoto, Kenji ^a   Shimomura, Hideki ^b   Yamashita, Takuro ^c   Hokamaki, Jun ^d   Tsunoda, Ryusuke ^d   Shiraishi, Shinya ^a   Yamashita, Yasuyuki ^a   Ogawa, Hisao ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Fukuoka Tokushukai Hospital   (Japan)

^c Department of Dermatology Omuta Tenryo Hospital   (Japan)

^d JAPANESE RED CROSS KUMAMOTO HOSPITAL   (Japan)

^e Division of Cardiovascular Medicine Diabetes Care Center Jinnouchi Hospital   (Japan)

Author keywords

Reperfusion; Scintigraphy; ST elevated acute myocardial infarction; Statin

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BRAIN NATRIURETIC PEPTIDE; CLOPIDOGREL; CREATINE KINASE; IODOFILTIC ACID I 123; LOW DENSITY LIPOPROTEIN CHOLESTEROL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROSUVASTATIN; THALLIUM 201; TICLOPIDINE; FATTY ACID; FLUOROBENZENE; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IODOBENZENE; IODOFILTIC ACID; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE; THALLIUM; UBIDECARENONE; UBIQUINONE;

ACUTE HEART INFARCTION; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR PARAMETERS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; EMERGENCY CARE; FEMALE; FIBRINOLYTIC THERAPY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REPERFUSION; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYOCARDIAL PERFUSION IMAGING; MYOCARDIAL SALVAGE INDEX; ONSET TO BALLOON TIME; OPEN STUDY; PILOT STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TIME; TIME TO TREATMENT; AGED; ANALOGS AND DERIVATIVES; BLOOD; CHEMICAL PHENOMENA; CHEMISTRY; CLINICAL TRIAL; DRUG EFFECTS; ECHOCARDIOGRAPHY; HEART; HEART MUSCLE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PATHOLOGY; SCINTISCANNING;

AGED; CHOLESTEROL, LDL; ECHOCARDIOGRAPHY; FATTY ACIDS; FEMALE; FLUOROBENZENES; HEART; HEPTANOIC ACIDS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IODOBENZENES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; PILOT PROJECTS; PROSPECTIVE STUDIES; PYRIMIDINES; PYRROLES; RADIONUCLIDE IMAGING; SULFONAMIDES; THALLIUM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; UBIQUINONE;

EID: 84907882575     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.08.053     Document Type: Article

References (40)

1. Van de Werf F., Bax J., Weis M., et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the task force on the management of ST-segment elevation acute myocardial infarction of the European society of cardiology. Eur Heart J 2008, 29:2909-2945.
2. LaRosa J.C., Grundy S.M., Wenger N.K., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. NEngl J Med 2005, 352:1425-1435.
3. Reiner Z., Catapano A.L., Wood, et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and the European atherosclerosis society (EAS). Eur Heart J 2011, 32:1769-1818.
4. Perk J., De Backer G., Zannad F., et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Atherosclerosis 2012, 223:1-68.
5. Reiner Z. Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol 2013, 10:453-464.
6. Schwartz G.G., Olsson A.G., Stem T., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711-1718.
7. Cannon C.P., Braunwald E., Skene A.M., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. NEngl J Med 2004, 350:1495-1504.
8. Sakamoto T., Kojima S., Kitagawa A., et al. Usefulness of hydrophilic vs lipophilic statins after acute myocardial infarction. Subanalysis of MUSAAHI-AMI. Circ J 2007, 71:1348-1353.
9. Frohlich G.M., Meier P., Hausenloy D.J., et al. Myocardial reperfusion injury: looking beyond primary PCI. Eur Heart J 2013, 34:1714-1722.
10. Takano H., Mizuma H., Komuro I., et al. Effects of pitavastatin in Japanese patients with chronic heart failure: the Pitavastatin heart failure study (PEARL Study). Circ J 2013, 77:917-925.
11. Tavazzi L., Maggioni A.P., Tognoni G., et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1231-1239.
12. Marcoff L., Thompson P.D. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. JAm Coll Cardiol 2007, 49:2231-2237.
13. Katsiki N., Tziomalos K., Al Halzitolios, et al. Effect of HMG-CoA reductase inhibitors on vascular cell apoptosis: beneficial or detrimental?. Atherosclerosis 2010, 211:9-14.
14. Ichihara K., Satoh K. Disparity between angiographic regression and clinical event rates with hydrophobic statins. Lancet 2002, 359:2195-2198.
15. Guijarro C., Blanco-Colio L.M., Egido J., et al. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998, 83:490-500.
16. Satoh K., Takguchi A., Ichihara K., et al. Effects of rosuvastatin and pitavastatin on ischemia-induced myocardial stunning in dogs. JPharm Sci 2008, 106:593-599.
17. Thygesen K., Alpert J.S., Al-Attar N., et al. Universal definition of myocardial infarction. Circulation 2007, 116:2634-2653.
18. Patti G., Pasceri V., Di Sciascio G., et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. JAm Coll Cardiol 2007, 49:1272-1278.
19. Yamashita S., Yamamoto Y. Simultaneous detection of ubiquinol and ubiquinone in human plasma as a marker of oxidative stress. Anal Biochem 1997, 250:66-73.
20. Yoshinaga K., Matsuki T., Tamaki N., et al. Validation of automated quantitation of myocardial perfusion and fatty acid metabolism abnormalities on SPECT images. Circ J 2011, 75:2187-2195.
21. Cerqueira M.D., Weissman N.J., Verani M.S., et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the cardiac imaging committee of the council on clinical cardiology of the American heart association. Circulation 2002, 105:539-542.
22. Satoh K., Ichihara K. Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs. JCardiovasc Pharmacol 2000, 35:256-262.
23. Granger C.B., Weaver W.D. Reducing cardiac events after acute coronary syndromes. Rev Cardiovasc Med 2004, 5(Suppl.5):S39-46.
24. Sheiban I., Fragasso G., Trevi G., et al. Time course and determinants of left ventricular function recovery after primary angioplasty in patients with acute myocardial infarction. JAm Coll Cardiol 2001, 38:464-471.
25. Okazaki S., Yokoyama T., Daida H., et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study. Circulation 2004, 110:1061-1068.
26. Miyauchi K., Kimura T., Matsuzaki M., et al. Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): rationale and design. Circ J 2006, 70:1624-1628.
27. Baseline serum cholesterol and treatment effect in the scandinavian simvastatin survival study (4S). Lancet 1995, 345:1274-1275.
28. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The long-term intervention with pravastatin in ischaemic disease (LIPID) study group. NEngl J Med 1998, 339:1349-1357.
29. Sacks F.M., Pfeffer M.A., Braunwald E., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. NEngl J Med 1996, 335:1001-1009.
30. Post S., Post M.C., Doevendans P.A., et al. Early statin treatment prior to primary PCI for acute myocardial infarction: REPERATOR, a randomized placebo-controlled pilot trial. Catheter Cardiovasc Interv 2012, 80:756-765.
31. Hahn J.Y., Kim H.J., Gwon H.C., et al. Effects of atorvastatin pretreatment on infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J 2011, 162:1026-1033.
32. Yeagle P.L. Lipid regulation of cell membrane structure and function. FASEB J 1989, 3:1833-1842.
33. Kaufmann P., Torok M., Krahenbuhl S., et al. Toxicity of statins on rat skeletal muscle mitochondria. Cell Mol Life Sci 2006, 63:2415-2425.
34. Demyanets S., Kaun C., Wojta J., et al. Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes invitro. Biochem Pharmacol 2006, 71:1324-1330.
35. Ichihara K., Satoh K., Abiko Y. Influences of pravastatin and simvastatin, HMG-CoA reductase inhibitors, on myocardial stunning in dogs. JCardiovasc Pharmacol 1993, 22:852-856.
36. Carnicka S., Adameova A., Ravingerova T., et al. Distinct effects of acute pretreatment with lipophilic and hydrophilic statins on myocardial stunning, arrhythmias and lethal injury in the rat heart subjected to ischemia/reperfusion. Physiol Res 2011, 60:825-830.
37. Toyama K., Sugiyama S., Ogawa H., et al. Rosuvastatin combined with regular exercise preserves coenzyme Q10 levels associated with a significant increase in high-density lipoprotein cholesterol in patients with coronary artery disease. Atherosclerosis 2011, 217:158-164.
38. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature 1990, 343:425-430.
39. Molyneux S.L., Florkowski C.M., Richards A.M., et al. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. JAm Coll Cardiol 2008, 52:1435-1441.
40. Lee E., Ryan S., Schneck D., et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005, 78:330-341.